暫無數據
代碼股票名稱
最新價漲跌額升跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日升跌幅10日升跌幅20日升跌幅60日升跌幅120日升跌幅250日升跌幅年初至今升跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
自選模擬交易
美股市場個股詳情
DXR Daxor
- 9.890
- +0.606+6.53%
收盤價 11/25 16:00 (美東)
4786.81萬總市值8.53市盈率TTM
9.990最高價9.002最低價9.60萬股成交量9.100今開9.284昨收91.73萬成交額4.57%換手率70.64市盈率(靜)484.01萬總股本10.04052周最高1.47市淨率2080.03萬流通值7.16052周最低--股息TTM210.32萬流通股24.076歷史最高--股息率TTM10.64%振幅3.400歷史最低9.550平均價1股每手
盤前分時
- 5日
- 日線
- 周線
- 月線
- 季K
- 年K
資金分布
單位: --
資金流向
實時日周月
暫無數據
新聞
daxor的創新性BVA-100血容量診斷特色板塊於MEDAXIOm CV TRANSFORUm FALL '24展出
精英心血管領袖聯合：通過共享卓越推動創新 奧克嶺，田納西州，2024年10月09日 (全球貨幣新聞社) -- daxor公司 (納斯達克: DXR)，全球血容量領先者
daxor公司將參加2024年麥斯姆保健虛擬峯會的爐邊聊天
daxor將重新提交血容量分析儀平台的510(k)申請
快訊 | Daxor公司 - 撤回雙重510(K)/Clia豁免申請
daxor 公司爲開創性診斷設備優化了監管策略
公司將專注於獲得510(k)批准路徑，加速上市時間奧克里奇，田納西州，2024年9月27日（全球新聞社）-- 納斯達克daxor公司（NASDAQ:DXR），全球血容量測量技術領先者，今天
daxor公司將參展2024年美國心力衰竭學會年會
2024年9月19日，田納西橡樹嶺（Oak Ridge, TN）（全球新聞通訊社）— daxor公司（納斯達克:DXR）, 全球血液容積測量技術領導者, 今日宣佈參加年度科學會議。
評論
$Daxor (DXR.US)$ daxor的創新BVA-100血液體積診斷特色板塊在MEDAXIOm CV TRANSFORUm FALL '24中亮相
GlobeNewswire·
精英心血管領袖聯合：通過共享卓越推動創新
Daxor公司（NASDAQ: DXR）是全球血液成交量測量技術的領導者，在2024年10月9日於田納西州奧克嶺宣布，今天將在MedAxiom心血管（CV）Transforum Fall'24會議上展示。
GlobeNewswire·
精英心血管領袖聯合：通過共享卓越推動創新
Daxor公司（NASDAQ: DXR）是全球血液成交量測量技術的領導者，在2024年10月9日於田納西州奧克嶺宣布，今天將在MedAxiom心血管（CV）Transforum Fall'24會議上展示。
已翻譯
$Daxor (DXR.US)$
Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management
Daxor (Nasdaq: DXR) announces a pivotal review published in Cardiorenal Medicine highlighting the important role of Blood Volume Analysis (BVA) in managing cardiorenal syndrome (CRS). The review, authored by expert contributors, emphasizes BVA's significance in enhancing the precision of diuretic and red cell therapies, leading to impro...
Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management
Daxor (Nasdaq: DXR) announces a pivotal review published in Cardiorenal Medicine highlighting the important role of Blood Volume Analysis (BVA) in managing cardiorenal syndrome (CRS). The review, authored by expert contributors, emphasizes BVA's significance in enhancing the precision of diuretic and red cell therapies, leading to impro...
$Daxor (DXR.US)$
Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri...
Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri...
$Daxor (DXR.US)$
NEWS
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Daxor (Nasdaq: DXR) announces two new studies validating the clinical benefits of blood volume analysis (BVA) in ambulatory heart failure patients. The studies highlight the lack of correlation between surrogate measures and actual blood volume, emphasizing the importance of accurate volume measurement. Data presented at th...
NEWS
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Daxor (Nasdaq: DXR) announces two new studies validating the clinical benefits of blood volume analysis (BVA) in ambulatory heart failure patients. The studies highlight the lack of correlation between surrogate measures and actual blood volume, emphasizing the importance of accurate volume measurement. Data presented at th...
1
Hello everyone,
We're seeking community insights on the potential movement of this stock in the coming one to two months. Do you anticipate it to rise or fall?
If you have any solid ideas, insider information, or news that might influence this stock's direction, kindly share in the comments section below. Your input is greatly valued!
Thank you for your participation.
$Daxor (DXR.US)$
We're seeking community insights on the potential movement of this stock in the coming one to two months. Do you anticipate it to rise or fall?
If you have any solid ideas, insider information, or news that might influence this stock's direction, kindly share in the comments section below. Your input is greatly valued!
Thank you for your participation.
$Daxor (DXR.US)$
1
閱讀更多
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
升跌幅
暫無數據